DDInter1570 DDInter1296
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.
Ranolazine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is upregulated by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Ranolazine {u} (Compound) causes {v} (Side Effect) Gait disturbance
Gait disturbance {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Lomitapide {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Dexamethasone
Dexamethasone {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) resembles {v} (Compound) Eprazinone
Eprazinone {u} (Compound) resembles {v} (Compound) Bepridil
Bepridil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Bupivacaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Lorlatinib {u} may lead to a major life threatening interaction when taken with {v} Nintedanib
Ranolazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Ranolazine (Compound) causes Gait disturbance (Side Effect) and Gait disturbance (Side Effect) is caused by Lomitapide (Compound) and Lomitapide may lead to a major life threatening interaction when taken with Nintedanib
Ranolazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dexamethasone (Compound) and Dexamethasone may lead to a major life threatening interaction when taken with Nintedanib
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) resembles Eprazinone (Compound) and Eprazinone (Compound) resembles Bepridil (Compound) and Bepridil may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Ranolazine (Compound) resembles Bupivacaine (Compound) and Bupivacaine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Nintedanib